Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Opinion|Videos|August 7, 2024

The Role of ADT in Localized or Locally Advanced Prostate Cancer

Author(s)Lawrence Karsh, MD, FACS, Stephen J. Freedland, MD, Terence Friedlander, MD

3. Terence Friedlander, MD, provides clinical insights on factors that inform the role for androgen deprivation therapy in the treatment of patients with localized or locally advanced prostate cancer.

Episodes in this series

Lawrence Karsh, MD, FACS, an expert on prostate cancer

EP. 1 Prostate Cancer Treatment: The Evolving Therapeutic Landscape

Stephen Freedland, MD, an expert on prostate cancer

EP. 2 The Heterogeneity of Prostate Cancer

Stephen Freedland, MD, an expert on prostate cancer

EP. 3 The Role of ADT in Localized or Locally Advanced Prostate Cancer

Stephen Freedland, MD, an expert on prostate cancer

EP. 4 EMBARK Study: ADT in Nonmetastatic Castration-Sensitive Prostate Cancer

Stephen Freedland, MD, an expert on prostate cancer

EP. 5 Treatment Considerations in Nonmetastatic CSPC

Terence Friedlander, MD, an expert on prostate cancer

EP. 6 Combination Therapies and Intensifications of ADT in Advanced Prostate Cancer

Terence Friedlander, MD, an expert on prostate cancer

EP. 7 Treatment Options in Castration-Resistant Prostate Cancer

Terence Friedlander, MD, an expert on prostate cancer

EP. 8 The Relationship Between Prostate Cancer and Cardiovascular Disease

Stephen Freedland, MD, an expert on prostate cancer

EP. 9 Impact of GnRH Agonists and Antagonists on Cardiovascular Outcomes in Prostate Cancer

Lawrence Karsh, MD, FACS, an expert on prostate cancer

EP. 10 ADT Treatment Considerations and Unmet Needs in Prostate Cancer

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Ridwan I. Alam, MD, MPH, discusses combining PHI and MRI to predict prostate cancer risk

ByRidwan I. Alam, MD, MPH

January 22nd 2026

CaverSTIM device shows initial promise for post-prostatectomy erectile dysfunction

ByHannah Clarke

January 21st 2026

Initial ARID results published in World Journal of Urology as pivotal trial progresses

ByHannah Clarke

January 20th 2026

Iman Sadri, MD, discusses novel nerve grafting strategy for erectile dysfunction after prostatectomy

ByIman Sadri, MD, CM

January 19th 2026

The UroOnc Minute: Diet and Prostate Cancer, with Stephen J. Freedland, MD

ByAdam B. Weiner, MD,Stephen J. Freedland, MD

January 16th 2026

Latest CME

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

February 23, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Trending on Urology Times

FDA grants 510(k) clearance to Break Wave lithotripsy device for kidney stones

Practical guide to female pelvic organ–sparing radical cystectomy

Lina Posada Calderon, MD, provides insights on germline BAP1–associated renal cell carcinoma

CaverSTIM device shows initial promise for post-prostatectomy erectile dysfunction

Targeting BCG resistance in high-risk NMIBC